Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Dennis A Revicki & William R Lenderking. (2012) Methods and issues associated with the use of quality-adjusted life-years. Expert Review of Pharmacoeconomics & Outcomes Research 12:1, pages 105-114.
Read now
Read now
Articles from other publishers (19)
Sara Alonso, Isla Morante, Mercedes Alperi & Rubén Queiro. (2022) The ASAS Health Index: A New Era for Health Impact Assessment in Spondyloarthritis. The Journal of Rheumatology 49:1, pages 8-15.
Crossref
Crossref
Uta Kiltz, David Kiefer & Annelies Boonen. (2020) (Health-Related) Quality of Life as an Outcome in Studies of Axial Spondyloarthritis. Rheumatic Disease Clinics of North America 46:2, pages 379-393.
Crossref
Crossref
Ivette Essers, Mickael Hiligsmann, Uta Kiltz, Nick Bansback, Juergen Braun, Desirée van der Heijde & Annelies Boonen. (2019) Development of one general and six country-specific algorithms to assess societal health utilities based on ASAS HI. RMD Open 5:1, pages e000872.
Crossref
Crossref
John J. Dziak. 2018. Optimization of Behavioral, Biobehavioral, and Biomedical Interventions. Optimization of Behavioral, Biobehavioral, and Biomedical Interventions
207
267
.
Paula K. Lorgelly, Brett Doble, Donna Rowen & John Brazier. (2016) Condition-specific or generic preference-based measures in oncology? A comparison of the EORTC-8D and the EQ-5D-3L. Quality of Life Research 26:5, pages 1163-1176.
Crossref
Crossref
George E. MacKinnonIIIIIIPatricia van Hanswijck de Jonge & Donald E. Stull. 2017. Understanding Health Outcomes and Pharmacoeconomics. Understanding Health Outcomes and Pharmacoeconomics.
Olivia ErnstssonPetter TinghögKristina AlexandersonJan HillertKristina Burström. (2017) The External Validity of Mapping MSIS-29 on EQ-5D Among Individuals With Multiple Sclerosis in Sweden. MDM Policy & Practice 2:1, pages 238146831769280.
Crossref
Crossref
Elizabeth Goodwin & Colin Green. (2016) A Systematic Review of the Literature on the Development of Condition-Specific Preference-Based Measures of Health. Applied Health Economics and Health Policy 14:2, pages 161-183.
Crossref
Crossref
Irina Cleemput & Mattias Neyt. (2015) WHICH QUALITY OF LIFE MEASURES FIT YOUR RELATIVE EFFECTIVENESS ASSESSMENT?. International Journal of Technology Assessment in Health Care 31:3, pages 147-153.
Crossref
Crossref
Dennis Lendrem, Sheryl Mitchell, Peter McMeekin, Simon Bowman, Elizabeth Price, Colin T Pease, Paul Emery, Jacqueline Andrews, Peter Lanyon, John Hunter, Monica Gupta, Michele Bombardieri, Nurhan Sutcliffe, Costantino Pitzalis, John McLaren, Annie Cooper, Marian Regan, Ian Giles, David Isenberg, Saravanan Vadivelu, David Coady, Bhaskar Dasgupta, Neil McHugh, Steven Young-Min, Robert Moots, Nagui Gendi, Mohammed Akil, Bridget Griffiths & Wan-Fai Ng. (2014) Health-related utility values of patients with primary Sjögren's syndrome and its predictors. Annals of the Rheumatic Diseases 73:7, pages 1362-1368.
Crossref
Crossref
Gareth Furber, Leonie Segal, Matthew Leach & Jane Cocks. (2013) Mapping scores from the Strengths and Difficulties Questionnaire (SDQ) to preference-based utility values. Quality of Life Research 23:2, pages 403-411.
Crossref
Crossref
Sarah L. Shingler, Paul Swinburn, Andrew Lloyd, Jose Diaz, Robert Isbell, Stephanie Manson & Charlotte Benson. (2012) Elicitation of health state utilities in soft tissue sarcoma. Quality of Life Research 22:7, pages 1697-1706.
Crossref
Crossref
Gianluca Baio. 2012. Bayesian Methods in Health Economics. Bayesian Methods in Health Economics
133
170
.
CHARLES NORMAND. (2012) Setting priorities in and for end-of-life care: challenges in the application of economic evaluation. Health Economics, Policy and Law 7:4, pages 431-439.
Crossref
Crossref
Matthijs M. VersteeghAnnemieke LeunisJolanda J. LuimeMike BoggildCarin A. Uyl-de GrootElly A. Stolk. (2011) Mapping QLQ-C30, HAQ, and MSIS-29 on EQ-5D. Medical Decision Making 32:4, pages 554-568.
Crossref
Crossref
Javier Soto ÁlvarezJavier Soto Álvarez. 2012. Evaluación económica de medicamentos y tecnologías sanitarias:. Evaluación económica de medicamentos y tecnologías sanitarias:
105
125
.
Jennifer Petrillo, Floortje van Nooten, Paul Jones & Maureen Rutten-van Mölken. (2011) Utility Estimation in Chronic Obstructive Pulmonary Disease. PharmacoEconomics 29:11, pages 917-932.
Crossref
Crossref
Ralph Crott & Andrew Briggs. (2010) Mapping the QLQ-C30 quality of life cancer questionnaire to EQ-5D patient preferences. The European Journal of Health Economics 11:4, pages 427-434.
Crossref
Crossref
Murali Sundaram, Michael J. Smith, Dennis A. Revicki, Lesley-Ann Miller, Suresh Madhavan & Gerry Hobbs. (2010) Estimation of a Valuation Function for a Diabetes Mellitus-Specific Preference-Based Measure of Health. PharmacoEconomics 28:3, pages 201-216.
Crossref
Crossref